Table 2.
Lactate:pyruvate ratios in Type 2 diabetic hearts
| Group | n | Lactate/Pyruvate ratio |
| Non-diabetic controls | 12 | 16.8 ± 3.2 |
| Type 2 diabetics | ||
| 12 weeks duration | 9 | 41.4 ± 8.8* |
| 48 weeks duration | 5 | 77.5 ± 12.2* |
| Aldose reductase inhibited Type 2 diabetics | ||
| 12 weeks duration | 7 | 7.2 ± 1.8 |
| 48 weeks duration | 5 | 10.5 ± 3.2 |
| Sorbitol dehydrogenase inhibited Type 2 diabetics | ||
| 12 weeks duration | 7 | 8.9 ± 2.1 |
| 48 weeks duration | 5 | 12.6 ± 3.4 |
* p < 0.05 vs non-diabetic controls. The lactate/pyruvate ratios were measured after perfusion for one hour under normoxic conditions.